IMMUNOTHERAPY

Catherine Bollard, MBChB, MD, from the Baylor College of Medicine, discusses T cells and TGF-beta in Hodgkin's lymphoma and Non-Hodgkin lymphoma.

Paul A. Bunn, Jr, MD, from the University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor mutation.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Pazopanib was better tolerated with noninferior efficacy when compared to sunitinib as a treatment for patients with advanced renal cell carcinoma.

Elizabeth Mittendorf, MD, PhD, from the University of Texas MD Anderson Cancer Center, gives an overview of how the E75 vaccine works in breast cancer.

Renier J. Brentjens, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the potential efficacy of CAR-modified T cells for the treatment of solid tumors.

The investigational immunotherapy Allovectin (velimogene aliplasmid) failed to meet key endpoints in a phase III trial in patients with stage III/IV metastatic melanoma.

Roy S. Herbst, MD, PhD, from the Yale Cancer Center, describes immunotherapy as one of the most exciting advances in cancer care.

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, discusses the exploration of immunotherapies as treatments for patients with advanced lung cancer.

Silvia Novello, MD, PhD, from the University of Turin, Italy, gives an overview of immunotherapy and the targeting of the MAGE-A3 protein in lung cancer.

Lynn M. Schuchter, MD, describes two trials presented at the 2013 ASCO Meeting looking at nivolumab in patients with melanoma.

Andrew T. Parsa MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for recurrent glioblastoma multiforme.

Cameron J. Turtle, MD, PhD, from the Fred Hutchinson Cancer Research Center, discusses the design of a chimeric antigen receptor (CAR).

Studies have confirmed that dysregulation of apoptosis is implicated in the pathogenesis of many diseases. Deficient apoptosis is key in the development of cancer.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.

Robert Andtbacka, MD, from the University of Utah School of Medicine and Huntsman Cancer Institute, discusses a trial analyzing talimogene laherparepvec (T-VEC) in melanoma.

Andre Goy, MD, from John Theurer Cancer Center, discusses recent research into fighting cancer with the immune system.

A phase III study of Revlimid in combination with dexamethasone in patients with newly diagnosed multiple myeloma met its primary endpoint of PFS.

The next-generation PI3 kinase (PI3K) inhibitor GDC-0032 has shown signs of efficacy in patients with advanced cancers that were mutated for the PI3K alpha gene.

The anti-PD-1 therapy nivolumab demonstrated an overall objective response rate of 31%, with a median duration of 2 years in patients with advanced melanoma.

Howard L. Kaufman, MD, Rush University Medical Center, comments on the changing outlook for immunotherapies.

Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from a phase I trial investigating the anti-PD-1 monoclonal antibody nivolumab.

The recent approval of the second-generation proteasome inhibitor carfilzomib by the FDA comes nine years after the initial approval of bortezomib, the first-in-class drug of its type.

In advance of the 2013 ASCO Annual Meeting, Targeted Healthcare spoke with Mike Thompson, MD, PhD, about the use of social media in the field of oncology.

Antoni Ribas, MD, PhD, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.